Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.
Abstract: Administering an amino acid-containing composition, containing the following amino acids (1)-(9), wherein the molar content ratio of each amino acid to the total content of the amino acids (1)-(9) falls within the following numerical ranges: (1) leucine 35-66%; (2) isoleucine 5.0-15%; (3) valine 5.0-15%; (4) threonine 7.0-14%; (5) lysine 8.0-16%; (6) methionine 2.0-10%; (7) histidine 0.1-3.5%; (8) phenylalanine 2.5-8.0%; and (9) tryptophan 0.1-2.0%, is effective for enhancing recovery from muscle fatigue.
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
June 29, 2021
Assignee:
GENMAB A/S
Inventors:
Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Type:
Grant
Filed:
September 24, 2020
Date of Patent:
February 9, 2021
Assignees:
AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
Inventors:
Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
Abstract: The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Type:
Grant
Filed:
January 23, 2017
Date of Patent:
February 9, 2021
Assignee:
INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
Inventors:
Hemanta Baruah, Cheng Chen, Xiaolin Liu, Andy Tsun, De-Chao Michael Yu
Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
October 6, 2020
Assignee:
GENMAB A/S
Inventors:
Bart De Goeij, Edward N. Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
Abstract: The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition.
Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
September 29, 2020
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
Abstract: Methods of simultaneously excising large nucleic acid sequences from a target nucleic acid and inserting large foreign nucleic sequences into the target nucleic acid sequence using DNA binding protein nucleases are described.
Type:
Grant
Filed:
June 30, 2014
Date of Patent:
September 29, 2020
Assignee:
President and Fellows of Harvard College
Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
September 29, 2020
Assignee:
SEATTLE GENETICS, INC.
Inventors:
May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
September 8, 2020
Inventors:
Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.
Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
August 18, 2020
Assignee:
NOVARTIS AG
Inventors:
Matthew John Edwards, Jean-Michel Rene Rondeau, Danforth Miller, Daniel Huang, Hans-Peter Knopf, Gino Anselmus Van Heeke, Rene Hemmig, Kapil Gupta, Nicole Haubst, Barbara Andlauer
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
August 18, 2020
Assignees:
Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
Type:
Grant
Filed:
July 18, 2014
Date of Patent:
August 4, 2020
Assignees:
CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
Type:
Grant
Filed:
January 4, 2018
Date of Patent:
August 4, 2020
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
Type:
Grant
Filed:
June 30, 2014
Date of Patent:
July 21, 2020
Assignee:
President and Fellows of Harvard College
Inventors:
Prashant G. Mali, George M. Church, Luhan Yang